Direct Sales Helps Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. reported that its Over-the-Counter Drug division ("OTC Division") successfully entered into supply contracts with more than five hundred drug stores in Beijing as of today. Lotus Pharmaceuticals, Inc. currently has direct purchase contracts in place with approximately 300 manufacturers nationwide to distribute more than 800 types of medicines.  The Company also believes it will be able to enter into purchase agreements with a total of roughly 900 manufacturers throughout the PRC by the end of 2012.

"I'm pleased with the experienced sales force of our OTC Division," said Dr. Zhong Yi Liu, Chairman and Chief Executive Officer of the Company. "Since the establishment of the OTC Division at the end of the last year, we have demonstrated substantial success in entering this new market segment in Beijing. Our market research shows that the current sales revenue for 4,500 drug stores in Beijing is estimated to be in the aggregate RMB 5 billion per year. Looking forward, we believe that our revenues generated from direct sales to drug stores could contribute around RMB 60 million to net revenues by the end of 2010 with an estimated 25% in net margin."

Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. More than 8,000 products are sold by Liang Fang directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces. 

Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website

About Best Damn Penny Stocks

Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.

Please click here to read the full disclaimer